Ionis Pharma Announces Publication Of Positive Donidalorsen Data For Angioedema Attacks

Ionis Pharmaceuticals Inc IONS announced the publication of Phase 2 data for donidalorsen in the New England Journal of Medicine (NEJM).
Donidalorsen is an investigational antisense medicine under development for hereditary angioedema (HAE), a disorder characterized by recurrent episodes of severe swelling.
In the Phase 2 study, donidalorsen demonstrated a 90% reduction in angioedema attacks compared with placebo at the 80 mg monthly dose.
There was a significant improvement in quality of life as assessed by the Angioedema Quality of Life Questionnaire (AE-QoL) in the patients treated with donidalorsen.
Also See: Pfizer, Ionis Discontinue Vupanorsen Clinical Development Program.
Donidalorsen is designed to reduce the production of prekallikrein, which plays a crucial role in the activation of inflammatory mediators associated with acute attacks of HAE.
The data showed that the mean monthly rate of angioedema attacks was 0.23 and 2.21 in patients receiving donidalorsen and placebo, respectively.
The mean attack rate between Weeks 5 and 17 was 0.07 and 2.06.
Most adverse events during the study were mild, with a similar frequency between patients receiving donidalorsen and placebo groups.
Price Action: IONS shares traded 1.03% higher at $34.33 premarket on the last check Thursday.